MarketWatch.com - MarketPulse
SAN FRANCISCO (MarketWatch) -- Schering-Plough Corp. and Johnson & Johnson Inc. unit Centocor Inc. said Friday they revised a 1998 distribution agreement on the anti-imflammatory medication Remicade, and golimumab, a therapy in late development at Centocor. Upon regulatory approval of golimumab in the European Union, the companies said Schering-Plough's rights to sell Remicade in certain markets outside the United States will extend beyond 2014. Centocor will also get an increased profit share on Schering-Plough's sales of both products between 2010 and 2014.